What it is
Semaglutide is a GLP-1 receptor agonist — a medication that mimics the action of a gut hormone (glucagon-like peptide-1) released after eating. It slows gastric emptying, increases satiety, reduces appetite and food noise, and has metabolic effects on glucose handling. It is FDA-approved under different brand names for type 2 diabetes and, separately, for chronic weight management in patients meeting clinical criteria.
It is a real medication with real effects, real side effects, and real candidacy criteria. It is not a cosmetic shortcut.
For patients considering peptide-based weight management more broadly — semaglutide alongside tirzepatide and newer agents — see the Weight Loss Peptides page. This page is specific to semaglutide as a single-agent protocol at Esvie.
How Dr. Brown approaches it
Semaglutide at Esvie is prescribed inside a structured protocol, not handed out as an injection on demand. The first visit is a clinical consultation: medical history, current medications, weight history, what has and has not worked, prior workup, and a focused exam. Baseline labs are ordered when indicated. Contraindications — personal or family history of medullary thyroid cancer or MEN 2, history of pancreatitis, severe gastrointestinal disease, eating disorder history, pregnancy — are screened directly.
If semaglutide is appropriate, dosing follows a titration schedule designed to minimize gastrointestinal side effects. Patients are given specific guidance on protein intake, hydration, resistance training, and what side effects warrant a call versus a same-day evaluation. Follow-up visits — typically monthly during titration, then on a defined cadence — track weight, body composition where appropriate, side effects, and whether the protocol is meeting your goals.
If semaglutide is not appropriate, or if the right starting point is a different intervention — nutrition counseling first, evaluation by an internist or endocrinologist, or a different agent — Dr. Brown will say so.
What to expect
Initial visit: Roughly thirty to forty-five minutes. History, exam, screening for contraindications, lab orders when indicated, review of expectations and side effects, and informed consent.
Starting therapy: Semaglutide is administered as a once-weekly subcutaneous injection. Most patients self-administer at home after instruction; some prefer in-office administration during titration.
Titration: Dose is escalated on a defined schedule based on tolerance and response. Going up too fast is the most common cause of unnecessary nausea. The schedule is set with the goal of finding the lowest effective dose, not the maximum dose.
Side effects: Nausea, early satiety, constipation, reflux, and fatigue are the most common, most pronounced during dose changes, and usually improvable with hydration, smaller meals, fiber, and pacing. Anything sudden or severe — particularly abdominal pain — is evaluated promptly.
Follow-up: Monthly during titration is typical. The follow-up cadence after stable dosing is set at consultation. Therapy is not open-ended; the plan and the exit are defined together.
Candidacy
Good candidates meet clinical criteria for medical weight management, have engaged with lifestyle change without reaching their goals, and are willing to participate in the protocol — not just receive the prescription.
Not a candidate during pregnancy, nursing, or planned pregnancy in the near term. Not a candidate with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, active severe gastrointestinal disease including gastroparesis, or an active or untreated eating disorder. Not a candidate when the goal is cosmetic weight loss outside a clinical indication.
If semaglutide is not the right tool for your situation, Dr. Brown will direct you to what is — whether that is a different medical protocol, a referral, or a focused conversation about lifestyle change first.